Comparison of breast cancer HER-2 receptor testing with immunohistochemistry and in situ hybridization

Purpose Human epidermal growth factor receptor–2 (HER2) status can be tested with immunohistochemistry (IHC) and in situ hybridization (ISH). The 2018 American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) HER2 testing guidelines suggest initial HER2 testing using IHC and...

Full description

Saved in:
Bibliographic Details
Published in:Breast cancer research and treatment 2023-02, Vol.198 (1), p.143-148
Main Authors: Shanmugalingam, Aswin, Hitos, Kerry, Pathmanathan, Nirmala, Edirimmane, Senarath, Hughes, T. Michael, Ngui, Nicholas K.
Format: Article
Language:English
Subjects:
Biomarkers, Tumor - metabolism
Biopsy
Breast cancer
Breast Neoplasms - diagnosis
Breast Neoplasms - genetics
Breast Neoplasms - metabolism
Cancer research
Comparative analysis
Epidemiology
Epidermal growth factor
ErbB-2 protein
Female
Health aspects
Humans
Hybridization
Immunohistochemistry
In Situ Hybridization
In Situ Hybridization, Fluorescence
Invasiveness
Medical societies
Medicine
Medicine & Public Health
Oncology
Receptor, ErbB-2 - genetics
Receptor, ErbB-2 - metabolism
Retrospective Studies
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose Human epidermal growth factor receptor–2 (HER2) status can be tested with immunohistochemistry (IHC) and in situ hybridization (ISH). The 2018 American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) HER2 testing guidelines suggest initial HER2 testing using IHC and further testing IHC equivocal cases with ISH. However, many institutions perform both IHC and ISH on the same specimen. This study aims to analyze the concordance between HER2 IHC and ISH in order to evaluate the benefit of repeating HER2 testing on the same breast cancer specimens. Method Patients diagnosed with invasive breast cancer through BreastScreen NSW Sydney West program between January 2018 and December 2020 were identified and their HER2 IHC and HER2 ISH results on core needle biopsy (CNB) and surgical excisions (SE) were retrospectively collected. Specimens with both IHC and ISH results were then analyzed for agreement and concordance using unweighted kappa values. Equivocal IHC (2+) cases were excluded from concordance analysis. Results Overall, there were 240 invasive breast cancer specimens (CNB and SE) with both IHC and ISH recorded. Concordance between HER2 IHC and ISH was 100% (95% CI: 96.2–100%; κ  = 1.00 (P 
ISSN:0167-6806
1573-7217
DOI:10.1007/s10549-023-06860-z